The GOLGB1 Knockout A-549 Polyclonal Cells product is a polyclonal population of A-549 human lung adenocarcinoma cells engineered by CRISPR/Cas9-mediated disruption of the GOLGB1 gene. As a polyclonal knockout pool, it retains the intrinsic heterogeneity of the parental cell line while providing a loss-of-function model for Giantin. This product enables the study of GOLGB1-dependent cellular processes without clonal selection artifacts.
A-549 is an epithelial cell line derived from the lung adenocarcinoma tissue of a 58-year-old Caucasian male. It serves as a widely used model for non-small cell lung cancer (NSCLC) research, including investigations into tumor progression, metastasis, and drug responses. The adherent cells express typical adenocarcinoma markers and are amenable to genetic manipulation, making them a suitable host for examining the role of Golgi-associated proteins in cancer.
GOLGB1 encodes the golgin Giantin, a critical structural protein that maintains Golgi ribbon architecture by mediating cisternal stacking and inter-cisternal vesicle tethering. Giantin interacts directly with GOLGA2/GM130 and USO1/p115, forming complexes that are essential for proper Golgi organization. Its function is regulated by cell cycle kinases CDK1 and PLK1, as well as ERK signaling, and is executed in concert with the small GTPase RAB1, COPI complex subunits such as ARF1 and COPG1, and other trafficking machinery. Knockout of GOLGB1 disrupts these interactions, leading to Golgi fragmentation and impaired protein trafficking and secretion.
In lung adenocarcinoma, GOLGB1 loss-of-function models are instrumental for understanding how Golgi structure impacts cancer cell behavior. The knockout A-549 cells exhibit altered secretion profiles that can affect the release of matrix-degrading enzymes, growth factors, and signaling molecules, thereby influencing migration, invasion, and tumor-stroma interactions. This model provides a physiologically relevant platform to dissect the contribution of Golgi integrity to the malignant phenotype, offering insights into potential vulnerabilities of cancer cells with dysregulated protein trafficking.
Typical experimental approaches for this model include western blotting and immunofluorescence to verify Giantin protein depletion and Golgi fragmentation, as well as electron microscopy for detailed ultrastructural examination. Functional assays such as protein secretion measurement (luminescence-based reporters or ELISA), cell viability under chemotherapeutic challenge, and migration/invasion assays are directly applicable. The polyclonal nature of the knockout pool allows the study of heterogeneous population responses, offering advantages for drug screening campaigns focused on Golgi-disrupting compounds or agents targeting secretion-dependent cancers. For additional technical information or to inquire about custom services, please contact Ascent Research.
